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Cystic fibrosis transmembrane conductance regulator (CFTR) is an unusual
ABC transporter. It acts as an anion-selective channel that drives osmotic
fluid transport across many epithelia. In the gut, CFTR is crucial for main-
taining fluid and acid-base homeostasis, and its activity is tightly controlled
by multiple neuro-endocrine factors. However, microbial toxins can disrupt
this intricate control mechanism and trigger protracted activation of CFTR.
This results in the massive faecal water loss, metabolic acidosis and dehydra-
tion that characterize secretory diarrhoeas, a major cause of malnutrition and
death of children under 5 years of age. Compounds that inhibit CFTR could
improve emergency treatment of diarrhoeal disease. Drawing on recent struc-
tural and functional insight, we discuss how existing CFTR inhibitors function
at the molecular and cellular level. We compare their mechanisms of action
to those of inhibitors of related ABC transporters, revealing some unexpected
features of drug action on CFTR. Although challenges remain, especially
relating to the practical effectiveness of currently available CFTR inhibitors,
we discuss how recent technological advances might help develop therapies to
better address this important global health need.
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CFTR (cystic fibrosis transmembrane conductance reg-
ulator, or ABC-C7), an unusual ABC transporter that
functions as an anion channel [1], controls fluid move-
ment across epithelia [2]. Loss-of-function mutations
in CFTR cause the dehydrated secretions characteristic
of the genetic disease cystic fibrosis (CF) [3]. In con-
trast, during life-threatening enterotoxin-mediated
secretory diarrhoeas, over-activation of CFTR causes
excessive fluid secretion across intestinal epithelia [4].
Diarrhoeal diseases are the second most-common
cause of death in young children worldwide. Oral
rehydration therapy is very effective. However, where
extreme poverty, natural disaster and/or war impede
provision of safe water, fatality rate increases
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dramatically (http://www.who.int/en/news-room/fact-
sheets/detail/diarrhoeal-disease). CFTR inhibitors have
been shown in model systems to rapidly block fluid loss
during enterotoxin-mediated diarrhoeas (e.g., cholera
[5]), and could be useful in preventing fatal dehydration
and further disease spread. Here we consider whether
they could help in the Global Action Plan towards elim-
inating childhood preventable deaths (https://www.who.
int/maternal_child_adolescent/news_events/news/2013/ga
ppd_launch/en/) when used alongside existing preventive
interventions and therapies.
Excellent reviews cover the development, pharmaco-
dynamic and pharmacokinetic aspects of existing
CFTR inhibitors [6–9]. This paper does not aim at
being comprehensive. Rather, we focus on mechanism
of inhibition, by selecting a small number of com-
pounds, targeting both CFTR and related ABC trans-
porters, which have been investigated in depth.
Comparisons of inhibitor mechanisms can shed light
on both CFTR and pump protein dynamics, and could
inform efforts aimed at developing improved therapies.
CFTR is a unique ABC system
CFTR is, so far, the only ABC transporter known to
function as a channel: it can form an aqueous ion con-
duction pathway that permits the flow of anions across
the plasma membrane down their electrochemical gra-
dient [10]. Structurally, CFTR nevertheless shares
highly conserved domains and an overall fold with
many transporter relatives [1].
Domain structure of CFTR
The CFTR coding sequence includes two homologous
halves, each formed by a transmembrane domain
(TMD) followed by a highly conserved cytosolic
nucleotide binding domain (NBD). CFTR has a typi-
cal type IV core fold [11], with each TMD comprising
6 transmembrane helices (TMs). But in CFTR the two
halves are linked by a ~ 200 amino acid-long domain
with no homology to other proteins, the R-domain.
Some evidence suggests that the emergence of CFTR’s
channel function coincided with the acquisition of the
R-domain [12]. Indeed, the R domain plays an impor-
tant role in controlling ion-channel function: CFTR
becomes active only following phosphorylation of
specific R domain serine residues, mainly by cAMP-de-
pendent (and cGMP in the intestine, see CFTR in
intestinal epithelia) protein kinases.
As in other ABC systems, binding of ATP at the
NBDs favours the formation of a ‘head-to-tail’ NBD1/
NBD2 dimer, with two nucleotide-binding sites at the
interface. The covalently-linked γ-phosphate forms
molecular contacts with both NBDs, stabilizing the
dimer [13]. Formation of the NBD dimer is associated
with conformational changes in the TMDs that result
in opening of the ion conduction pathway, as detailed
below. An active site, capable of catalysing hydrolysis
of the β–γ phosphate bond, is also formed in this
dimerized state thus triggering NBD dimer dissociation
to complete the conformational cycle [14]. CFTR
belongs to a large group of asymmetric ABC trans-
porters, which have only one catalytically active
nucleotide-binding site [15], including canonical, con-
served sequence motifs at the NBD1/NBD2 interface
(canonical site 2). The other interfacial site (noncanon-
ical, or degenerate site 1) binds ATP tightly, but has
lost hydrolytic activity, due to a number of nonconser-
vative substitutions in the sequence motifs [1].
Gates, channels and pumps
In both pumps and channels, conformational changes
result in the movement of specific gate structures. When
closed, these block substrate/ion access to the transloca-
tion/permeation pathway. For pumps, which couple the
energy releasing process of ATP hydrolysis to the ther-
modynamically uphill movement of a substrate against
an electrochemical gradient, it is crucial that none of
the conformations visited physiologically form a contin-
uous cytosol-to-extracellular pathway, a pore that
would allow dissipation of the generated gradient [16].
Indeed, experimentally observed ABC transporter
conformations (obtained using X-ray crystallography
and electron cryo-microscopy, cryo-EM) mainly
belong to two classes, each one presenting at least one
closed gate [11,17]. Inward facing (IF) conformations,
in which the NBDs are separated and the TMDs con-
verge at the extracellular side of the membrane, have
mostly been obtained in the absence of nucleotides.
These reveal a closed outer gate, as the translocation/
permeation pathway is continuous with the cytosolic
solution but not with the extracellular space. By con-
trast, in structures largely obtained in the presence of
ATP and under conditions that prevent hydrolysis, the
cytosolic TMD extensions have been drawn together
by NBD dimerization. These are outward-facing (OF)
conformations where the TMDs form tight helical
bundles on the cytosolic side of the translocation/per-
meation pathway. In OF conformations, the inner gate
is shut, closing access from the cytosol. In some struc-
tures, both inner and outer gates are closed, forming
an ‘occluded’ substrate-binding site closed off to both
sides of the membrane (e.g. [18,19]). For simplicity,
herein we classify conformations characterized by
dimerized NBDs as belonging to the OF group.
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Overall, this evidence supports the ‘alternating access’
model of transporter function, with hydrolytic cycles
at the NBDs driving coupled conformational changes
in the TMDs that gate the translocation pathway in
an alternating manner and result in unidirectional
transport of substrate across the membrane.
The CFTR channel shares some of the molecular
mechanisms used by its pump relatives. However,
while in pumps conformational changes are stoichio-
metrically coupled to the movement of one or a few
substrate molecules, in CFTR the homologous confor-
mational changes associated with ATP binding and
hydrolysis open and close a continuous permeation
pathway, directly linking cytosolic and extracellular
spaces. In other words, CFTR has only one functional
gate. Once this gate is open, millions of anions can
flow per second, down their electrochemical gradient,
without needing further slow protein movements to get
past a second gate.
Structural snapshots of CFTR
Patch-clamp studies, in which gate opening and closing
can be followed in real time on individual channels,
have revealed that in CFTR, gate opening follows
ATP binding at site 2 and is coupled to formation of a
tight NBD1/NBD2 dimer [20]. The interface tightens
around the ATP bound at site 2 early during the open-
ing transition, while movement around site 1 is more
delayed [21,22]. Finally, hydrolysis of the ATP mole-
cule bound at site 2 triggers NBD dimer dissociation
and gate closure [23]. Atomic-resolution structures of
full-length CFTR have largely confirmed these earlier
studies linking NBD dynamics to movement of the
channel gate, but have also revealed some idiosyncratic
characteristics of this unique ABC system.
As in other ABC systems, IF conformations with
separated NBDs (Fig. 1A,B) and OF conformations
with a tight NBD1/NBD2 dimer (Fig. 1C,D) have
been observed. Each TMD includes two short ‘cou-
pling helices’ (CHs) at the far intracellular end of the
TMs. These are positioned within depressions in the
NBDs to form ‘ball-and-socket’ joints. For each
TMD, the most C-terminal CH ‘domain-swaps’:
CH1 + CH4 interface with NBD1, CH2 + CH3 with
NBD2 (Fig. 1B). The residues involved in anion per-
meation delineate a clear permeation pathway [24],
consistent with results from decades of functional
Fig. 1. Structural snapshots of CFTR. (A) Cartoon representation of IF CFTR conformation, based on the dephosphorylated, ATP-free cryo-
EM model of human CFTR (PDB ID5UAK, [27]). TMD1-NBD1, green; TMD2-NBD2, teal. Some residues mentioned in text are shown as
coloured spheres. Also highlighted is the unwound portion of TM8 (magenta). The density corresponding to the R domain, which in this
conformation is located between the two TMDs, at a level below the cytosolic face of the membrane (grey band), is omitted for clarity. (B)
Schematic representation of IF conformation shown in A. Numbers indicate positions of transmembrane helices. (C) Schematic
representation of OF, open channel CFTR conformation. ATP is shown in yellow. The degenerate site 1 is here on the front, while canonical
site 2, also occupied by ATP, is on back (not shown). Here, an open anion permeation pathway is indicated (dotted blue line), based on
extensive functional evidence linking NBD dimerization to channel opening. However, we still lack structural evidence of a corresponding
OF, open-pore CFTR conformation, as in PDB ID6MSM, see D, the extracellular end of the permeation pathway is obstructed. (D) Cartoon
representation of phosphorylated, ATP-bound human E1371Q-CFTR (6MSM, [30]). The R domain density is again not shown. In this view it
lies on the back of the protein, at a level below the lasso domain (here visible as the short helix parallel to the plane of the membrane, on
right of image).
4087FEBS Letters 594 (2020) 4085–4108 ª 2020 The Authors. FEBS Letters published by John Wiley & Sons Ltd
on behalf of Federation of European Biochemical Societies
H. R. de Jonge et al. CFTR inhibitors for secretory diarrhoeas
experiments (reviewed in Refs [25,26]). As expected,
dephosphorylated, ATP-free conformations show sepa-
rated NBDs and a permeation pathway closed off on
the extracellular side [24,27]. The extracellular CFTR
gate is closed [28,29]. In these IF conformations, the R
domain is detected as a largely unstructured electron-
dense region which occupies space in between the two
structural halves (TMs 1, 2, 3, 6, 10, 11 with NBD1
and TMs 7, 8, 9, 12, 4, 5 with NBD2, Fig. 1B). Effec-
tively, the dephosphorylated R domain sterically hin-
ders the IF-to-OF transition driven by formation of an
NBD1/NBD2 dimer and therefore prevents the open-
ing of the gate.
R domain phosphorylation causes a shift in the R
domain density [30,31]. In the phosphorylated struc-
tures (obtained in the presence of ATP and carrying
the E1371Q mutation that prevents hydrolysis), as
observed for the OF conformations of other Type IV
ABC systems, the two structural halves have rotated
towards each other and a typical head-to-tail NBD
dimer is formed (Fig. 1C). Atypically, however, in
CFTR NBD-dimerized, OF structures, the inner gate
is not closed: access to the permeation pathway from
the cytosol is provided by a bypass ‘portal’ that opens
between TM4 and TM6 [32,33].
Another unusual feature, present in both IF and
OF CFTR structures, is an unwound segment in
TM8. This displaces TM7, and forms a groove on
the membrane-facing surface of the TMDs. Even
CFTR’s close pump relative, multidrug resistance-as-
sociated protein 1 (MRP1 or ABC-C1), does not
share this feature [27]. Microsecond-long molecular
dynamics simulations with the protein embedded in a
lipid bilayer suggest the unwinding of TM8 is rela-
tively stable [34].
Finally, OF CFTR structures were found to have a
closed extracellular gate. This was unexpected, as a
large body of experimental evidence suggests that the
conditions in which the structures were obtained (fol-
lowing phosphorylation, in the presence of Mg2+ATP,
with Walker B catalytic site 2 ‘E-to-Q’ mutation
E1371Q) strongly stabilize a conformation with an
open permeation pathway [20]. It is possible that the
absence of a proper lipid bilayer during preparation of
the cryo-EM sample has altered the relative stability of
alternative conformations, and the OF cryo-EM struc-
tures reflect the conformation adopted in the physio-
logically short-lived intraburst closures [31], or a
relatively stable ‘pre-open’ conformation that con-
tributes to the final stretch of the long interburst
closed dwell-times observed in single-channel records
[35]. In any case, we do not have a complete molecular
understanding of CFTR’s open outer gate.
CFTR in intestinal epithelia
Transport processes in enterocytes
A vitally important function of mammalian intestinal
epithelia is the isotonic secretion of fluid and elec-
trolytes, consisting mainly of Na+, Cl− and HCO3
ions. This process not only promotes the enzymatic
digestion of nutrients and prevents dehydration of the
epithelial surface and intestinal obstruction but, in
concert with the propulsive movements of the intesti-
nal smooth muscle, also serves to protect the intestinal
tract against noxious agents, including bacteria and
their enterotoxins.
The secretory function is confined mainly to the
crypt region and is anatomically separated from the
villus compartment whose major transport function is
the Na+- or H+-coupled absorption of digestive prod-
ucts and the reabsorption of water and electrolytes
(see model Fig. 2 and [36]). Like in most other Cl−
secreting epithelia, the Na+, K+ ATPase in the basolat-
eral membrane of the crypt cells provides the driving
force for Cl− entry via the electroneutral cotransporter
NKCC1 (Fig. 2A). K+ recycles back through basolat-
eral K+ channels (KCNQ1; KCNN4), and Cl− exits
the cell via the CFTR Cl− channel in the apical mem-
brane, a process that can be measured in vitro in Uss-
ing chambers as a change in the electrical potential
difference across the epithelium or, in voltage-clamp
mode, as a short-circuit current (Isc). Similarly, HCO

3
can enter the cell via Na+-coupled electrogenic
(NBCe1) or electroneutral (NBCn1) cotransporters
and exit the cell via CFTR or Cl=HCO3 exchangers
of the SLC26 family (SLC26A3/DRA; SLC26A6/PAT-
1). Passive Na+ secretion occurs paracellularly through
cation-selective tight junctions between the cells, in
response to the lumen-negative transepithelial potential
difference resulting from active, transcellular anion
secretion. The resulting osmotic gradient drives passive
water movement across the ‘leaky’ tight junctions
(Fig. 2A).
Under physiological conditions, intestinal elec-
trolyte and fluid secretion from the crypts is in bal-
ance with reabsorption in the villus (Fig. 2B).
However, in a pathological condition named secretory
diarrhoea (SD) secretion is hyperstimulated and
absorption inhibited in response to endogenous or
exogenous secretagogues, including microbial toxins
such as cholera toxin and Escherichia coli enterotox-
ins (see [36] for a complete list). In human SD, fluid
loss can exceed 1 Lh−1, resulting in rapid systemic
dehydration, metabolic acidosis, hypokalemia, and
cardiac and renal failure [4].
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The key player in most forms of human SD is the
CFTR anion channel. In CF, loss-of-function muta-
tions in CFTR cause a severe impairment of Cl− and
HCO3 secretion in virtually all epithelial tissues and
the complete loss of electrolyte and water secretion
in intestinal epithelium in which compensatory apical
anion channels are lacking ([37,38]; Fig. 2). The high
propensity of CF patients to develop intestinal block-
ade, manifesting as meconium ileus in newborns and
distal intestinal obstruction syndrome in adults, illus-
trates the key role of CFTR in intestinal electrolyte
and fluid homeostasis and identifies this channel, or
components of its activation mechanism, as suitable
targets for antidiarrhoeal drug therapy [39,40].
Localization and function of CFTR
As illustrated in Fig. 3, the CFTR protein is highly
expressed in the apical membrane of crypt epithelial
cells, along the whole length of the intestine. Single cell
RNASeq and functional studies confirm that CFTR is
already expressed highly in LGR5+ intestinal stem cells
at the bottom of the crypt and remains high in all
stem cell-derived cell lineages with the clear exception
of mucin-secreting goblet cells and absorptive entero-
cytes ([41,42]; cf. Fig. 3). Furthermore, in human and
rat, but not in mouse proximal small intestine, a very
rare cell type termed ‘CFTR high-expresser’ (CHE)
cell, resembling pulmonary ionocytes in the airways
Fig. 2. Location in enterocytes of ion transporters and cyclic nucleotide signalling cascades involved in enterotoxin-induced intestinal
electrolyte and fluid secretion. (A) CFTR-mediated vectorial anion secretion in CFTR-enriched crypt cells. The Na+,K+-ATPase provides the
driving force for basolateral Cl−andHCO3 entryviaNa
+-coupled cotransport, mediated by NKCC1 and NBCe1/NBCn1, respectively.
Cl−andHCO3 exit the cellviaCFTR. In addition,HCO

3 also exits the cellviaCl
=HCO3 exchangers (DRA, PAT-1; not shown). Transcellular,
electrogenic anion secretion generates a lumen-negative transepithelial potential difference (VTE) that drives passive paracellular
Na+secretion. The resulting osmotic gradient drives water movement across the tight junctions. Salt and water secretion are regulated by a
plethora of neuro-endocrine factors that control protein kinase-mediated phosphorylation/activation of CFTR. (B) NHE3- and DRA-mediated
NaCl absorption in villus cells. In villus cells, the coordinated activity of NHE3 andCl=HCO3 exchangers (SLC26A3/DRA; and SLC26A6/PAT-
1, not shown) mediates vectorial NaCl uptake, which, in turn, promotes water absorption. cAMP- and cGMP-linked signal transduction
routes, that is the same pathways that activate CFTR (also present in the upper epithelium, but at comparatively low levels; see Fig. 3A),
inhibit NHE3 and promoteHCO3 secretion. The regulation ofCl
=HCO3 exchangers is less well defined. AC, adenylyl cyclase; GC-C, guanylyl
cyclase C; H, hormone or para-/neurocrine factor; PKA, cAMP-dependent protein kinase, PKG2, cGMP-dependent protein kinase 2; PDE3,
phosphodiesterase 3.
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[43], has been identified ([44]; Fig. 3A). Its precise
function has not been elucidated yet but it could be
involved in cAMP- and Ca2+-regulated local Cl− and
fluid secretion serving to clear adherent mucus from
intervillous spaces and to facilitate nutrient absorption
in the villus compartment [44].
Whereas CFTR-mediated Cl− secretion serves to move
mucus and Paneth cell-derived defensins out of the
intestinal crypts, studies in CF animal models revealed
that CFTR-dependent HCO3 secretion is required for
the unfolding and release of mucins from neighbouring
goblet cells (stained negatively for CFTR; Fig. 3A,E) and
to prevent the formation of viscous and sticky mucus
[45]. In addition, CFTR acts as a tumour suppressor gene
by preventing intracellular alkalinization and hyperprolif-
eration of intestinal stem cells [42,46].
CFTR regulation by cAMP- and cGMP-dependent
protein kinases
Upon multisite phosphorylation of serine residues in
the R domain by membrane-bound isoforms of
cAMP- and cGMP-dependent protein kinases (PKA2
and PKG2, respectively), the R domain becomes more
disordered and no longer hinders conformational
changes needed for channel opening [31]. However, in
the intestine, in contrast to most other epithelial tis-
sues, increasing the open probability of the CFTR
channel is not the sole mechanism by which cAMP
and cGMP signalling stimulate CFTR function. The
microtubule-dependent recruitment of CFTR-rich
endosomal vesicles to the apical membrane, involving
molecular motor proteins like myosin 1a, is well docu-
mented in intestinal cell lines and native intestine and
results in a vast increase in the density of CFTR chan-
nels on the cell surface [47,48].
Whereas cAMP/PKA-induced phosphorylation and
activation of CFTR is rather universal among epithe-
lial tissues, cGMP-triggered activation is confined
mainly to enterocytes that express high amounts of the
type 2 isoform of PKG [49,50]. However, in cells in
which PKG2 is low or absent, for example in distal
colon or in the shark rectal gland, cGMP still activates
CFTR through cross talk to the cAMP signalling
Fig. 3. Immunodetection of CFTR in
human small intestine and colon. Jejunal
(panels A–D) and rectal (panels E and F)
biopsies were fixed in performic acid,
paraffine embedded and stained with the
polyclonal, affinity-purified hCFTR antibody
CC24 [165]. A rabbit specific horseradish
peroxidase (HRP)/3,30-diaminobenzidine
(DAB) detection IHC Kit (Abcam,
Cambridge, UK) was used to visualize
CFTR protein (brown stain). (A) CFTR
expression in jejunal villi showing (a) the
absence of CFTR staining in the apical
border of goblet cells, and (b) detection of
relatively rare CFTR high expressor (CHE)
cells (arrow heads). (C) High expression of
CFTR protein in the luminal membrane of
jejunal crypt cells. (E) CFTR staining in
mid-crypt cells of distal colon/rectum,
showing the absence of CFTR in goblet
cells. Panels B, D and F show the
absence of CFTR immunostaining in
biopsies from a homozygous F508del CF
patient, confirming the high specificity of
the CFTR antibody.
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pathway, either through cGMP activation of PKA or
through cGMP inhibition of cAMP hydrolysis by
phosphodiesterase 3, most plausibly PDE3B ([51,52];
Fig. 2). Whereas cGMP signalling in most tissues is
triggered by nitric oxide or atriopeptins, intestinal
cGMP formation is brought about by a unique class
of cysteine-rich luminocrinic peptides named guanylins
[36]. The two major isoforms, guanylin (GUCA2A)
and uroguanylin (GUCA2B), are produced locally by
multiple epithelial cell types along the rostrocaudal
and crypt-villus axes [53]. They act as nonabsorbable
fluid volume sensors and assist in maintaining fluid
homeostasis in the intestinal lumen by binding to a
receptor guanylyl cyclase (GC-C/GUCY2C) which is
co-localized with CFTR in the apical membrane
[54,55]. Binding of guanylins triggers conformational
changes in the catalytic domain of GC-C in the cell
interior resulting in local elevation of cGMP in close
proximity to the CFTR channel. This cGMP-linked
mode of Cl− secretion differs spatially from cAMP-in-
duced anion secretion in that most endogenous cAMP-
linked hormones and neurotransmitters, for example
VIP or prostaglandins, act through GS protein-coupled
activation of adenylyl cyclase isoforms located in the
basolateral membrane and require diffusion of cAMP
or the catalytic subunit of PKA2 to the target trans-
porters in the luminal membrane ([36]; cf. Fig. 2).
Importantly, cAMP- and cGMP-linked secreta-
gogues exert a dual action: they not only provoke
anion secretion by opening of the CFTR channel but
additionally inhibit Na+ absorption at the level of the
Na+/H+ exchanger NHE3, thereby contributing to net
electrolyte and fluid loss in SD ([56,57]; cf. Fig. 2).
Thus, inhibition of cAMP or cGMP signalling is a
more effective, albeit less selective, means of counter-
acting SD in comparison with direct targeting of
CFTR by CFTR inhibitors, because it not only results
in inhibition of secretion but additionally promotes the
restoration of NaCl and water absorption.
Involvement of CFTR in the pathophysiology of
enterotoxin-mediated diarrhoeas
Multiple enterotoxins secreted by pathogenic bacterial
strains colonizing the intestinal wall exploit the cAMP
or the cGMP signalling pathway in the enterocyte to
elicit excessive salt and water secretion as a flush-
through mechanism to promote their own dissemina-
tion. The classical example is a toxin secreted by patho-
genic strains of Vibrio cholerae, named cholera toxin
(CT), which belongs to the AB5 group of enterotoxins
[4,36]. Whereas the B pentamer binds to GM1 ganglio-
sides on the cell surface, causing the holotoxin to
internalize via caveolin-mediated endocytosis, the A
subunit becomes unfolded in the ER, is released by ret-
rograde transport into the cytosol, and catalyses NAD-
dependent ADP-ribosylation of the stimulatory G pro-
tein Gαs. This results in irreversible inactivation of the
GTPase site and sustained activation of adenylyl cyclase
isoform 6 (AC6) which is physically associated with
CFTR in the apical membrane [58]. This leads to a per-
manent elevation of cAMP, PKA and CFTR activity
and inhibition of NHE3 during the life span of the host
cell (~5 days for human enterocytes). However, due to
the rapid renewal of the intestinal epithelium enabled
by daily divisions of the stem cells at the bottom of the
crypt, cholera is a self-limiting disease [4,36].
Importantly, animal studies with labelled CT have
shown that penetration of the toxin into the intestinal
crypt, the main site of CFTR expression, is slow and
incomplete, but nevertheless the net fluid secretion eli-
cited by CT is abundant. This paradox was resolved
by the finding that CT is also able to stimulate ente-
rochromaffin (EC) cells in the villus compartment to
release 5-hydroxytryptamine (5-HT) which activates
VIPergic neurons in the myenteric plexus [59]. Both 5-
HT and VIP are potent secretagogues, acting at least
in part via the cAMP signalling cascade [36,59]. In
addition, activation of VIPergic neurons may evoke a
secreto-motor reflex in the enteric nervous system
(ENS), explaining why local CT instillation in the
small intestine can elicit fluid secretion in the colon
[60]. In summary, studies in animal models show that
up to 60% of the intestinal fluid secretory response to
CT can be explained by the stimulation of enteric
nerves [36,59]. Furthermore, the complete lack of CT-
induced secretion in the intestine of Cftr−/− mice illus-
trates that CFTR plays a central role in both ENS-de-
pendent and ENS-independent fluid secretion [61].
Of note, multiple other pathogens release CT-like
AB5 enterotoxins and cause cAMP-mediated SD. The
most notable of them, heat-labile enterotoxin (LT) is
produced by enterotoxigenic strains of E. coli (ETEC)
that cause 280 million cases of SD and 370 000 fatali-
ties per year, most of them young children [36].
Aside from CT, V. cholerae secretes many other tox-
ins and virulence factors that do not target CFTR but
contribute substantially to the pathogenesis of cholera.
They include the accessory cholera toxin (ACE) target-
ing the TMEM16F/ANO6 Cl− channel via a Rho-
GEF-RhoA-Rock-PIP5 kinase pathway [62], and the
zonula occludens toxin (Zot) and 2 other toxins that
polymerize or cross-link actin and destabilize the tight
junction component ZO-1 [36]. Importantly, because
none of these toxins acts through cAMP and CFTR,
their action is insensitive to CFTR inhibitors.
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Another major toxin elaborated by ETEC strains,
the heat-stable enterotoxin STa, is a small, poorly
immunogenic peptide of 18–19 amino acids containing
six cysteine residues and three disulfide bonds [55,63].
This toxin mimics the action of endogenously pro-
duced guanylins by binding in a reversible fashion to
the receptor domain of GC-C, resulting in cGMP for-
mation [64]. As predicted, mice deficient in GC-C are
STa- but not CT-resistant [65]. In contrast, PKG2
ablation in mice reduced the effect of STa on jejunal
Isc by 80%, but diminished jejunal fluid loss in vivo by
only 50%, most likely due to a CT-like action of STa
on 5-HT release by EC cells, followed by an ENS-me-
diated release of VIP that signals through cAMP, not
cGMP [66–68].
Despite the wealth of detailed information about the
molecular basis of SD summarized above, current
treatment options remain highly limited and new,
more effective pharmacological therapies are urgently
needed.
Current and potential therapies for secretory
diarrhoea
Oral rehydration solution
Vaccination campaigns and improved sanitation may
help to prevent or limit the devastating effects of a
cholera outbreak, but the current mainstay in treating
acute diarrhoeal diseases is the administration of an
oral rehydration solution (ORS). This inexpensive,
easy to implement remedy helped to reduce SD-related
mortality in children below 5 years of age from
4.6 million in 1980 to current levels of 1.2 million per
year worldwide [36,69]. The WHO-UNICEF-recom-
mended ORS formulation is hypotonic and contains
an equimolar solution of glucose and Na+ salts (NaCl
and Na-citrate). Its efficacy is due to the stimulation
of Na+-coupled glucose and fluid absorption via the
SGLT1 transporter, which is not inhibited by cAMP
or cGMP signals in the intestinal villi [36]. Active
SGLT1 also promotes the recruitment of NHE3 to the
apical membrane and uncouples it from CT/cAMP
inhibition via an AKT/NHERF2-dependent mecha-
nism, further stimulating NaCl and fluid absorption
[70]. ORS supplementation with Zn2+ and amylase-re-
sistant starch further improves the efficacy of ORS,
the latter acting by promoting the release and uptake
of short-chain fatty acids produced from starch by
commensal bacteria in the colon [71].
Unfortunately, despite its efficacy in systemic rehy-
dration, ORS does not reduce the duration or volume
of diarrhoea and therefore negatively affects
compliance to the therapy [72] and increases the risk
of further spread of infection. On the other hand, it
promotes the removal of the pathogen from the indi-
vidual and avoids accretion of fluid and dangerous dis-
tension of intestinal loops [4]. Clearly, new, safe,
effective and affordable drug therapies are needed to
complement or replace ORS, particularly to combat
traveller’s diarrhoea or SD in developing countries.
Such therapies should target crucial steps in the mech-
anism by which microbial enterotoxins cause SD in
the host, but avoid adverse or toxic side effects in the
intestine or other organs. Before discussing inhibition
of CFTR, hyperactivation of which plays a crucial role
in all types of human SDs, we present alternative
potential targets for therapy.
Inhibitors of other ion channels or transporters
One obvious class of potential antisecretory drug tar-
gets are the ion channels and transporters depicted in
Fig. 2. Aside from CFTR, other ion transporters suit-
able as drug targets in SD include the apical Na+/H+
exchanger NHE3, the basolateral Cl− importer
NKCC1, and the basolateral K+ channels KCNQ1
and KCNN4, which hyperpolarize the cell membrane
and enhance the electrical driving force for Cl− exit
through the CFTR channel [73]. A peptide that mimics
part of the NHE3 C-terminal domain and acts as a
dominant NHE3 agonist is under development and
could serve as a proabsorptive therapeutic [74]. NKCC
inhibitors such as bumetanide are already used as
diuretics in the clinic, counteracting their potential util-
ity in preventing SD-associated systemic dehydration.
However, if it is feasible to develop more selective
NKCC1 inhibitors that do not cross-react with
NKCC2, the major NKCC isoform in the kidney, such
compounds would offer great promise as novel
antidiarrhoeal medicine. Furthermore, K+ channel
inhibitors like the antifungal clotrimazole, approved
by the FDA for other indications, are other promising
candidates [75].
Inhibitors of cAMP signalling
Another antidiarrhoeal strategy is to target the molec-
ular mechanisms that regulate the activity or expres-
sion of the transport and channel proteins involved in
SD. However, targeting components of the cAMP sig-
nalling cascade has the disadvantage that only a subset
of them, that is GM1 receptors [76], LPA2 receptors
for lysophosphatidic acid (LPA) [36,77,78] and, poten-
tially, Ca2+-sensing receptors (CaSRs [79]), are located
on the luminal surface and are directly exposed to
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orally applied antidiarrhoeals. In contrast most other
potential targets, including adenylyl cyclase 6 (AC6;
[58]), farnesoid X receptors (FXR; [80]), somatostatin
and α2-adrenergic receptors [4,40], and PDZ adaptor
proteins (NHERF1-3; [56,68]) are located intracellu-
larly or in the basolateral membrane and are reachable
only by drugs that are effectively absorbed or adminis-
tered systemically. Because none of the components of
the cAMP signalling pathway is intestine-specific,
avoiding side effects of these drugs on other organs is
a major challenge.
Inhibitors of cGMP signalling
In comparison with anticholera drugs, pharmacologi-
cal inhibitors of STa-induced SD a priori offer several
advantages. First, STa binding to the receptor domain
of GC-C is reversible, implying that orally applied STa
receptor antagonists, either peptides or small mole-
cules, could potentially block STa-induced secretion
from the luminal side at any time during infection.
Secondly, the two major molecular candidate targets,
GC-C and PKG2, are highly expressed in the intestine
but are low or absent in most other tissues, explaining
why resistance to STa-induced SD is the sole pheno-
type of GC-C−/− mice and the major phenotype of
PKG2−/− mice [65–67]. Unfortunately, intensive efforts
to discover STa receptor antagonists by high-through-
put screening have failed so far, but another class of
GC-C activity blockers acting intracellularly have been
recently developed that inhibited STa-provoked anion
secretion in human intestinal biopsies but exhibited a
~ 100-fold lower potency for inhibition of the atri-
opeptin-target guanylyl cyclase A (GCA) and no inhi-
bitory effect on the NO-target soluble guanylyl cyclase
(sGC) [81]. Another potential approach is the use of
PKG2 blockers. A novel class of highly potent and
selective PKG2 inhibitors targeting the ATP-binding
pocket was developed recently on the basis of high-
throughput screening [82]. Unfortunately their inhibi-
tory potency in STa-induced SD is limited for two rea-
sons: at high concentrations, they elevate cAMP levels,
conceivably through inhibition of PDE activity [82];
and in most intestinal segments, STa/cGMP induces
secretion in part via PKA signalling which is not inhib-
ited by the PKG2 blockers (Fig. 2) [81].
ABC transporter inhibitor mechanisms
Inhibitors of several ABC transporters have been iden-
tified, and in some cases, studied in mechanistic and
structural detail. Particularly relevant here are inhibi-
tors of Type IV ABC systems [11], which have a TMD
fold very similar to that of CFTR. Because CFTR’s
unique channel nature allows in depth biophysical and
kinetic investigation, while other transporters are more
amenable to a variety of biochemical studies, compar-
isons of results obtained in different systems can pro-
vide insight from different perspectives and/or
highlight divergence in structure/function.
Zosuquidar: obstructing the IF-to-OF transition
Binding of inhibitor zosuquidar to P-glycoprotein
(ABC-B1) [83], and of the antidiabetic drug gliben-
clamide on sulfonylurea receptors (SUR1 or ABC-C8)
[18,84] show some similarity. In both cases, the inhibi-
tor occupies a binding site positioned in between the
two structural halves and therefore acts in a manner
broadly analogous to the dephosphorylated R domain
on CFTR, obstructing the IF-to-OF transition. How-
ever, the exact binding sites are different, and while
zosuquidar forms a large number of defined molecular
interactions with the target transporters, the gliben-
clamide-SUR1 and R domain-CFTR interactions are
looser, with the inhibitor likely adopting various con-
formations, suggesting differences in the details of the
mechanism of action.
Cryo-EM structures show the inhibitor zosuquidar
occupying the same cavity on ABC-B1 as transported
substrates, such as taxol. But why is taxol translocated
while zosuquidar interrupts the catalytic cycle? One
possibility is that the zosuquidar-ABC-B1 interaction
is too strong, restricting the protein’s dynamic flexibil-
ity: unlike taxol, the inhibitor forms a larger number
of contacts with the protein, fills the cavity completely
and maintains a precise pose, rather than sampling a
number of binding modes. Flexibility in the trans-
porter helices might be required to allow the TM rear-
rangement resulting in cavity reshaping and opening
of the outer gate. In addition, small structural changes
at the binding cavity are allosterically transmitted and
amplified (via TM7, TM8 and TM12) resulting in a
displacement of the CHs and NBD2 away from the
dimer interface (see fig. 2B–D in [83]). Curiously,
despite ABC-B1 having two canonical, catalytically
active sites, using double electron resonance spec-
troscopy, zosuquidar is found to be unable to stabilize
an asymmetric orthovanadate-trapped (see Orthovana-
date: interrupting the γ-phosphate splitting reaction
below) conformation in which one catalytic site (corre-
sponding to canonical site 2 in asymmetric trans-
porters) is tightly dimerized while the other is more
open. How much this asymmetric conformation is sta-
bilized correlates with how well different substrates
can stimulate ABC-B1 ATPase activity [85]. It is
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interesting to note that rate-equilibrium free-energy
relationship (REFER) analysis on CFTR suggests that
the highest energy conformation adopted by CFTR
during the channel-opening transition possesses an
already tightly dimerized canonical site 2, while move-
ments at site 1 are further behind [21]. It is possible
that for both symmetric and asymmetric type IV trans-
porters, adoption of an asymmetric transition-state
conformation facilitates overcoming the energetic bar-
rier associated with the IF-to-OF transition. Thus, the
reduced flexibility in ABC-B1’s TMDs, caused by tight
binding of zosuquidar, could be precluding access to a
favourable pathway in the energetic landscape linking
IF and OF conformations.
Orthovanadate: interrupting the γ-phosphate
splitting reaction
In several ABC transporters, hydrolytic activity can be
inhibited by incubation with orthovanadate (Vi), in the
presence of ATP and divalent cations. The Vi-depen-
dent inhibition of ABC-B1 was the subject of biochem-
ical studies, which elegantly demonstrated that
trapping of an ADP-Mg2+-Vi complex in a single
nucleotide binding site was sufficient to block further
hydrolytic cycles at both catalytic sites [86]. The ADP-
Mg2+-Vi complex is thought to mimic the high-energy
pentacovalent transition-state intermediate of the
phosphoryl-transfer reaction, specifically stabilized by
interactions within the active site [87,88].
However, although Vi efficiently blocks the catalytic
cycle of many ABC Transporters, resulting in an inhi-
bition of pump function, Vi action on wild-type CFTR
channels results in an increase in overall transmem-
brane anion flow. Because gate closure is triggered by
hydrolysis of the ATP molecule at site 2, which in turn
destabilizes the NBD1/NBD2 dimer and favours a
resetting of the protein to an IF conformation, Vi is
thought to ‘lock’ channels in an open conformation
(i.e., with unobstructed anion permeation pathway
[14,89,90]), by preventing hydrolysis and thus delaying
gate closure. Like Vi, pyrophosphate [91,92], poorly
hydrolysable nucleotide analogues [14] or mutations at
key catalytic residues in site 2 [93] all delay gate clo-
sure by preventing/slowing hydrolysis at site 2.
While the CFTR gating cycle is clearly a nonequilib-
rium process [23,94], the step corresponding to the γ-
phosphate splitting reaction is not necessarily irre-
versible [95], and Vi might reopen channels that have
recently closed [96]. However, the observation that a
conformational change in the permeation pathway (de-
tected as a single-channel conductance increase in
patch-clamp records) is prevented by the presence of
Vi, pyrophosphate, low [Mg
2+], or catalytic site 2
mutations [97], strengthens a gating model in which
hydrolysis at site 2 occurs on open channels, and is
what allows the relatively fast IF resetting, and there-
fore hydrolytic pore closure.
Inhibiting MsbA: obstructing IF-to-OF transition
and NBD uncoupling
MsbA is a Type IV system, involved in translocation
of lipopolysaccharide across the inner membrane in
Gram negative bacteria. Inhibition of MsbA holds
promise in view of novel antibiotic development. From
a screen of ~ 3 million compounds, Genentech scien-
tists identified a class of quinoline compounds capable
of inhibiting MsbA and displaying potent antibacterial
activity [98]. Crystal structures reveal two inhibitor
molecules bound to homologous sites on an MsbA
homodimer, poised in an IF conformation with rela-
tively close NBDs. The binding pocket is lodged
between TM4, TM5 and TM6 (see fig. 2 in [98]). Com-
parison with an OF MsbA structure [99] shows the
drug-binding pocket would be deformed in an OF con-
formation, suggesting that drug binding prevents the
IF-to-OF transition. In addition, though, comparison
with a drug-free IF cryo-EM MsbA structure [100]
reveals that drug binding distorts TM4 and TM5. The
distortion is transmitted allosterically along the TM
pair, shifting CH2 towards the central axis of the pro-
tein (see fig. 3d,e in [98]). This movement dislocates
one of the NBD/TMD ‘ball-and-socket’ joints: one
NBD is forced out of a network of conserved interac-
tions to avoid steric clashes with the other NBD. Thus
the quinoline inhibitors could block the MsbA pump-
ing cycle at two distinct steps: preventing the IF-to-OF
transition but also preventing the formation of active
catalytic sites at the NBD interface [98].
Because MsbA and CFTR share a type IV system
TMD fold, an image-based fluorescence assay was
used to test the effect of the quinoline compounds on
anion conductance in YFP-CFTR-expressing HEK293
cells (Fig. 4). Time course of the anion-sensitive YFP
quenching was measured following an iodide/chloride
exchange protocol [101,102]. Unexpectedly, the com-
pounds appear to activate CFTR, increasing cellular
anion conductance and depolarizing membrane poten-
tial. Like on MsbA, the (S)-enantiomer, G592, was
more efficacious than the (R)-enantiomer, G593
(paired t-test, n = 5, P = 0.020). However, G247,
which gives the highest potency on MsbA (IC50 =
5 nM, in which a naphthalene with a cyclopropane
substituent replaces the quinoline core of G592, see
fig. 1 in [98] for compound structures) appeared less
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efficacious on CFTR (paired t-test, n = 5, P = 0.003
vs. G592). G907 (which also presents an α -linked
cyclopropane ring) is very effective on CFTR and
potent on MsbA (IC50 = 18 nM). Like VX-770 [103],
the quinoline compounds are very lipophilic. We can-
not rule out that the micromolar concentrations tested
might have given rise to nonspecific effects due to
accumulation of drug in the membrane compartment.
However, the significantly different effects of the
equally lipophilic enantiomers G592 and G593, mirror-
ing their differing potencies on MsbA, are more con-
sistent with the drugs binding specifically to CFTR
and increasing its activity.
One interpretation of these results is that, unlike in
drug-bound MsbA, in drug-bound CFTR, the IF-to-
OF transition (corresponding to channel opening in a
normal CFTR gating cycle) can occur. CFTR would
thus enter an NBD-dimerized open state, but, because
of the displaced NBD and altered NBD1/NBD2 inter-
face, hydrolysis of the ATP at site 2 would be pre-
vented, locking CFTR in an open state. However, a
tight NBD dimer interface stabilizes the ground open
state and transition state for the CFTR opening step
[20,22]. It is difficult to envisage how these conforma-
tions would not be destabilized by NBD uncoupling.
Alternatively, drug-bound CFTR might be stabilized
in an IF conformation similar to that observed for
G907-bound MsbA, but in which the permeation path-
way is open. One of the two homologous drug-binding
sites seen on MsbA is located just extracellular to the
cytosolic portal bypassing the vestigial inner gate in
CFTR [32], and includes residues corresponding to
M348 and R352, part of CFTR’s inner vestibule
[104–106]. This site is also close to the unique
Fig. 4. Activation of CFTR by MsbA inhibitors. Acute treatment with selective quinoline MsbA inhibitors G592, G593, G247 and G907 [98]
results in an increase in cellular anion conductance. Functional analysis of wild-type YFP-CFTR expressed in HEK293 cells using an image-
based fluorescence microscopy assay [101,102]. YFP-CFTR is expressed from a pIRES2-mCherry-YFPCFTR plasmid, in which YFP-CFTR and
a soluble mCherry red fluorescent protein are translated from a single bicistronic mRNA. (A) Mean normalized CFTR conductance
(GCFTR_normalized) and cell membrane potential (VM) were estimated by fitting YFP quenching time course (see B), following extracellular
addition of iodide. Before iodide addition, a 230 s pretreatment allowed CFTR activation to reach a steady state. Bars represent different
pretreatment: vehicle control (DMSO, dark grey bar), 0.3 µMforskolin (light grey bar), 0.3 µMforskolin + 10 µMG592 (blue bar),
0.3 µMforskolin + 10 µMG593 (red bar), 0.3 µMforskolin + 10 µMG247 (yellow bar) or with 0.3 µMforskolin + 10 µMG907 (black bar) (n ≥ 5, as
indicated by solid circles, each representing one measurement obtained on an independent plate). To account for possible differences in
transfection efficiency between wells, CFTR conductance is normalized using the mean mCherry fluorescence measured within cells [102].
Data from wells belonging to the same 96-well plate were paired, and pairedt-tests were used to determine statistical significance of
comparisons (**P < 0.01; ****P < 0.0001). (B) Time course of YFP quenching following addition of extracellular iodide. Observed relative
fluorescence values are shown as yellow symbols, while solid lines are fits. For each compound, graphs compare quenching time curve
following pretreatment with vehicle control (squares, dark grey line), 0.3 µMforskolin alone (triangles, light grey line) and
0.3 µMforskolin + 10 µMcompound (circles, coloured line). Compound colour-coding as in A.
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unwound, hinge region of TM8 (Fig. 1), a region seen
to bind the approved CF potentiator drug VX-770
[107]. The quinoline compounds might affect the
dynamics of the helices surrounding the inner vesti-
bule, favouring the yet unknown conformational
changes needed to open the extracellular gate, stabiliz-
ing this open conformation and/or increasing the anion
throughput. It is interesting to note that some evidence
suggests that VX-770-bound CFTR might also have
noncanonical NBD/TMD interfaces [102,108].
CFTR inhibitor mechanisms
Considering its crucial role in CT-, LT-, and STa-in-
duced Cl− secretion, CFTR is a major target for the
development of antisecretory drugs. Multiple small-
molecule CFTR inhibitors have been identified [6–9],
and mechanism of action for a number of these have
been investigated (Fig. 5).
Glibenclamide: inner vestibule pore block
Glibenclamide, an antidiabetic drug targeting SUR1
(ABC-C8) in pancreatic β cells, has been shown to inhibit
CFTR when present on the cytosolic face of the mem-
brane. Patch-clamp records and alterations of gating
kinetics are consistent with an open-pore block [109,110]:
Fig. 5. Mechanism of action of CFTR and ABC transporter
inhibitors. (A) Gating of phosphorylated CFTR channels is driven by
ATPase cycles. In the absence of drugs, for phosphorylated, ATP-
gated wild-type CFTR channels, opening is coupled to formation of
a tight NBD1/NBD2 dimer; while channel closing is triggered by
ATP hydrolysis at site 2 (hidden in this view). In physiological
conditions, degenerate site 1 is likely not as open as seen
in5UAKand as depicted here [166]. (B) G907 binds between
TM4,5, 6 (and/or 10, 11, 12). While it inhibits MsbA, it increases
anion conductance of CFTR-expressing cells. Drug binding to CFTR
is here hypothesized to alter position of coupling helices, bringing
them closer together, and forcing a dislocation of ball-and-socket
joint with NBD1. Conformational changes at the extracellular end
of the inner vestibule result in an opening of the permeation
pathway. (C) Glibenclamide is an open-pore channel blocker,
whose binding site is within the membrane electric field. It
accesses its binding site from the cytosol, and apparent affinity
is increased by hyperpolarization. (D) At low micromolar
concentrations, GlyH-101 is a nonabsorbable open-pore channel
blocker, which acts from the luminal side of the membrane. Its
binding is favoured at depolarized membrane potential. (E) BPO-27
competes with ATP for binding at canonical site 2, preventing the
IF-to-OF transition, and therefore channel opening. (F) Binding of
CFTRinh-172 triggers a conformational change that leads to channel
closure (without requiring dissociation of NBDs). Here, this
conformational change is shown to close the cytosolic portal
between TM4 and TM6.
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binding of the drug within the permeation pathway in
open channel conformations, obstructs anion flow. The
anionic form is the active blocker, and hyperpolarizing
membrane potential favours block, suggesting a blocker
binding site located in the inner vestibule of the pore,
within the electric field of the membrane [110]. Similar
voltage-dependence, sensitivity to mutation and mutually
competitive interaction [111] suggest that a number of
other organic anions acting as blockers are subjected to
similar electrostatic interactions with positively charged
residues, including K95 [112], lining the relatively spa-
cious inner vestibule. In addition, permeant anions, still
carrying their hydration shells, also likely compete for
this dynamic binding site [113] along the permeation
pathway, explaining the influence of the Cl− gradient on
glibenclamide block [110].
While we do not have experimental structures con-
firming these functional inferences on CFTR, the bind-
ing of glibenclamide to SUR1 has been studied by
cryo-EM. Density corresponding to glibenclamide is
seen in the central cavity between the transmembrane
domains of the core of SUR1, which adopts an IF
conformation. Bound to SUR1, glibenclamide prevents
Mg2+-nucleotide stimulation of ATP-sensitive K+
channels (KATP) channels. It has been suggested that
bound glibenclamide might hinder NBD dimerization
and the IF-to-OF transition in SUR1 [114]. This
hypothesis is consistent with the glibenclamide-occu-
pied cavity shrinking in an NBD-dimerized, Mg2+
nucleotide-bound conformation [18].
However, the open-pore block characteristics of
glibenclamide inhibition of CFTR suggest that the
drug binds to the NBD-dimerized, OF open channel
[20] conformation. The two ABC-C subfamily proteins
have a similar overall core fold in TMD1 and TM10/
12 (CFTR) and 15/17 (SUR1), and several gliben-
clamide-contacting SUR1 residues (Y377, R1246,
W1297 [115]) are conserved in CFTR (I142, R1097,
W1145, respectively). The discovery of density corre-
sponding to the N terminus of the Kir6.2 subunit in
this region of the SUR1 central cavity [115], alongside
glibenclamide, raises a plausible scenario: as in ABC-
B1, the TMs surrounding the glibenclamide/substrate
binding cavity might need to undergo rearrangements
during the IF-to-OF transition, and the simultaneous
presence of the Kir6.2 N terminus and the drug might
be what is preventing these in SUR1. In CFTR, lack-
ing the inserted N-terminal peptide, the IF-to-OF tran-
sition can occur, giving rise to the pore-blocking
glibenclamide binding site, at a more extracellular
position in CFTR than in the glibenclamide-(SUR1-
Kir6.2)4 complex. The TM rearrangement could also
allow a reorientation of the elongated glibenclamide
molecule, so as to position the charged sulfonylurea
end of the drug close to K95 [112] and several posi-
tively charged TM6 residues [116] lining the intracellu-
lar vestibule (also cf. [117]).
Glycine hydrazides: extracellular pore block
The development of high-throughput assays to test
CFTR function in the Verkman laboratory [118]
opened the way to screening of large compound
libraries for the identification and development of
high-potency CFTR inhibitors. Glycine hydrazides
were among the first that were identified and a first
compound, GlyH-101 with low micromolar potency,
was developed. Again, kinetic analysis suggested that
the inhibitor bound to the open channel, causing pore
block, and the voltage-dependence of inhibition sug-
gested a binding site partly within the membrane elec-
tric field. However inhibition occurred following
extracellular application and apparent potency was
increased by depolarization of membrane potential
[119]. Slowing down of rates of reaction of thiol-reac-
tive compounds with F337C- and T338C-CFTR, fol-
lowing exposure to GlyH-101 [120], confirmed binding
to a site close to residues F337 and T338, positioned
at the extracellular end of the narrowest region of the
permeation pathway [121].
All these results are consistent with glycine hydrazides
binding in the outer mouth of the pore and causing
open-pore blockage. While a target site positioned on
the luminal face of enterocytes has some pharmacoki-
netic advantages, bypassing the requirement of systemic
absorption, mathematical modelling suggests that only
compounds possessing extremely high potency could
achieve the high levels of inhibition required in the pres-
ence of the intense convective washout fluxes typical of
SD pathology [122]. A number of macromolecular con-
jugates of glycine hydrazides have been developed (e.g.
[123]). These, by adding a moiety which binds to the gly-
cocalyx of enterocytes, resist intestinal washout. How-
ever, macromolecular conjugate drugs are not cheap to
produce nor stable without refrigeration, effectively lim-
iting the practical utility of these compounds for treat-
ment on the ground. A further potential obstacle in the
therapeutic use of GlyH-101 is its cytotoxicity observed
at suprapharmacological concentrations [124] (seen also
for CFTRinh-172).
Quinoxalinediones: competition at ATP-binding
sites
Pursuing the quest for extremely high-potency com-
pounds, the Verkman laboratory recently identified
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another class of CFTR-inhibiting compounds, the
PPQ/BPO compounds. Structure activity relationship
studies and chemical optimization led to the benzopy-
rimido-pyrrolooxazinedione BPO-27 molecule with an
IC50 below 10 nM.
The (R) enantiomer was found to be the active com-
pound [125], and patch-clamp studies confirmed an
IC50 below 5 nM for this stereoisomer. Application of
the inhibitor to the cytosolic face of the patch caused
a lengthening of the interburst closed dwell-times. In
addition, dose-response curves of currents obtained
with increasing concentrations of ATP were shifted to
higher [ATP] by the presence of (R)-BPO-27. The
results support a mechanism of action in which (R)
BPO-27 competes with ATP at the canonical ATP-
binding site, site 2, but drug binding fails to trigger
conformational changes resulting in opening of the
gate [126]. Docking and molecular dynamics studies
confirmed the presence of a favourable binding pocket
at the interface between the P-loop of NBD2 and the
signature sequence of NBD1 in an IF CFTR homol-
ogy model [33].
A study using mice intestinal loops and intestinal
epithelia demonstrated the efficacy of BPO-27 in pre-
venting CT- and STa- induced luminal accumulation
of fluid. No obvious toxicity was noticed in mice, at
concentrations giving adequate CFTR inhibition [127].
However, no careful investigation of selectivity was
carried out.
The consensus ATP-binding site is extremely con-
served in ABC transporters [11]. Because the residues
predicted to interact with BPO-27 are part of con-
served motifs (P-loop, A-loop, signature sequence)
selectivity for CFTR over other members of the super-
family needs to be verified. For instance, acute toxicity
might result due to BPO-27 competing with Mg2+-
ATP regulation of KATP channels (8/10 of the interact-
ing residues are identical in CFTR, ABC-C8, and
ABC-C9) or BPO-27 interference with the immune
response due to inhibition of TAP1/2 (binding site resi-
due identity: 6/10; conservation: 8/10).
Thiazolidinone: favouring closing of the inner
gate?
The first micromolar potency, CFTR-selective (not
affecting ABC-B1 or KATP activity), inhibitor discov-
ered through high-throughput screening was the thia-
zolidinone CFTRinh-172 [128], the mechanism of
action of which has been studied in depth.
Initial electrophysiological studies showed no effect
of the drug on single-channel conductance, nor on
open dwell-times. In addition, inhibition is voltage-
independent – all characteristics suggesting a mecha-
nism distinct from open-pore block. Instead, inhibition
reflects a reduction in open probability, and in particu-
lar a prolongation of interburst closed dwell-times.
However, unlike for BPO-27, inhibition by CFTRinh-
172 is not affected by [ATP] [129].
More in-depth studies revealed that CFTRinh-172
not only prolongs closed dwell-times but the com-
pound also affects open dwell-times, with increasing
concentrations of the drug causing a progressive short-
ening to a minimum. Inventive experiments demon-
strated that binding of the inhibitor could occur on
both open and closed channels, but apparent affinity
increased in conditions known to stabilize the NBD-
dimerized open state (catalytic site 2 mutations,
pyrophosphate, P-ATP). This suggested a tighter bind-
ing of the inhibitor to OF conformations. Binding of
the inhibitor did not prevent ATP control of the extra-
cellular gate, mediated by NBD dimerization. For
instance, ATP could remain trapped in inhibitor-closed
channels, revealed by their reopening, upon inhibitor
washout, without further addition of ATP; Inhibitor-
bound closed channels could open, upon ATP addi-
tion, but inhibitor presence was revealed by the shorter
open dwell-times. Thus, although CFTRinh-172 seemed
to close a gate distinct from the ATP-controlled gate,
the dynamics of the two gates were found to be cou-
pled. These considerations led Kopeikin and colleagues
to suggest that CFTRinh-172 might be favouring the
closing of the vestigial ‘inner gate’, homologous to
structures preventing substrate from having access to
the cytosol in OF conformations of CFTR’s pump rel-
atives [130].
Mutations that remove the positive charge at R347
(R347A, R347D) cause a dramatic decrease in
CFTRinh-172 potency, even when an open-pore stabi-
lizing salt bridge [131] is maintained (R347D/D924R)
[132]. The R347D mutation also reduces the potency
of a modified compound in which the negative charge
is removed, arguing against the charge of R347 inter-
acting directly with the carboxyphenyl group of the
bound inhibitor [132]. An allosteric effect of the muta-
tion seems more likely. Interestingly, the R347D muta-
tion has been shown to reduce ATPase activity [133].
The mechanism by which structural changes intro-
duced by the mutation (near the extracellular gate) are
transmitted to the catalytic site (at the NBD interface)
is unknown. But it is plausible that R347D might
allosterically interfere with NBD dimerization. If so,
the effects of the R347D mutation on CFTRinh-172
potency [132] would be consistent with the observed
correlation between propensity to adopt OF, NBD
dimerized, conformations and apparent affinity [130].
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Whether CFTRinh-172 binding to CFTR triggers con-
formational changes that close off the lateral portal
between TM4 and TM6 thus remains a question worth
further investigation.
Future development of therapies for
treatment of SD
Challenges
Considering the predominant incidence of diarrhoeal
diseases in developing countries, implying a low profit
potential for pharmaceutical companies, funding of the
development costs and costs of field trials for novel
antisecretory drug candidates remains a major chal-
lenge. Global cooperation between developed and
developing countries and philanthropic donations are
needed to overcome these hurdles. Repurposing drugs
that are already approved for other diseases or the use
of natural products could be a cost-effective alternative
strategy. In this respect, traditional medicine such as a
commonly used Thai herbal remedy [134], the diter-
penoid Oridonin [135], or Crofelemer, a proantho-
cyanidin oligomer isolated from the South American
Croton lechleri plant [136], all acting in part as CFTR
inhibitors, are attractive and inexpensive candidates.
When and where SDs are most lethal, good hygiene
conditions and efficient medical infrastructure are not
always available. Programmes aimed at developing an
effective CFTR-targeting pharmacological treatment,
to complement existing therapies, will need to take this
reality into account. In order for stocks to be available
and replenished regularly in remote, rural communities
worldwide, drugs would need to have a low produc-
tion cost, affordable to the health systems of develop-
ing countries. The active small-molecule would also
need to be stable, requiring little or no refrigeration or
protection from excessive humidity. Finally, oral
bioavailability is also an advantage, not requiring
skilled medical staff, nor high levels of cleanliness and
hygiene for safe administration. Given these require-
ments, pharmacokinetic optimization will inevitably
require considerable resources and will play a signifi-
cant part in the potential success of therapy on the
ground.
Unfortunately, many of the CFTR inhibitors so far
identified, upon oral administration, poorly penetrate
into the deep intestinal crypts, the major source of
CFTR-mediated fluid secretion, because of convective
washout with secreted fluid and abundant mucus [122].
Furthermore, because in the intestine from healthy
individuals, in contrast to CF patients, CFTR is not
rate-limiting for transepithelial Cl− and fluid secretion,
inhibition of CFTR activity needs to reach high levels
(probably > 80%) before the inhibitor starts to be
effective [38]. Both considerations together most plau-
sibly explain why the luminal addition of such small-
molecule CFTR blockers does not effectively block
cAMP-induced Cl− secretory currents in human rectal
biopsies but potently inhibits CFTR-mediated secre-
tory Cl− currents in monolayers of intestinal organoids
generated from these biopsies (Fig. 6).
Approaches to improve their efficacy may include
the combined use of mucolytics, or the encapsulation
of CFTR inhibitors inside acid-resistant nanoparticles.
Ideally, to prevent the systemic bioavailability of the
Fig. 6. Different potency of GlyH-101 analogue iOWH032 in human rectal biopsies as compared to 2D rectal colonoids originating from the
same individual. (A) Rectal biopsy specimens obtained from healthy individuals were mounted in Ussing chambers and short-circuit currents
(Isc), representing CFTR-mediated anion secretion, were assessed as described in detail elsewhere [81,82]. iOWH032, a GlyH-101 analogue
[40], was added only to the luminal bath; the cAMP agonist forskolin (F; 10 µM) and 3-isobutyl-1-methylxanthine (I; 100 µM) were added to
both the luminal and basolateral bath. (B) Undifferentiated colonoid monolayers derived from the rectal biopsies shown in panel A were
grown on Transwell filters and subsequently mounted in Ussing chambers.Iscmeasurements were performed as described for panel A. (C)
iOWH-032 mediated inhibition of the cAMP-dependentIscresponse in colon tissue (Tis.) and organoids (Org.), as assessed at the maximal
iOWH032 concentration tested in panels A and B. Horizontal bars depict mean  SD of 6 (Tis.) or 5 (Org.) experiments. Data were
statistically evaluated by ANOVA. The improved efficacy of iOWH032 in colonoid monolayers as compared to the rectal biopsies may have
multiple causes: (a) the flat structure of the monolayer, preventing convective washout of the inhibitor as occurs in intestinal crypts [122];
(b) the lack of goblet cells and therefore of a mucus barrier in undifferentiated intestinal organoids [167]; (c) CFTR is rate-limiting for the
forskolin/cAMP-induced anion secretory current in colonoids but not in rectal biopsies from healthy individuals [38].
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drugs and to restrict their action to the intestine, the
nanoparticles should be designed in such a way that
they become entrapped and degraded within lysosomes
rather than being exocytosed at the basolateral mem-
brane of the enterocyte [137]. Mucus-coated human
2D intestinal organoids (see below) are excellent novel
models to test such approaches.
Chronic administration of CFTR inhibitors might
raise concerns about toxicity (e.g. turning SD into CF
[138]), However, short-term treatment, preferably as
an adjuvant therapy to ORS, is expected to be suffi-
cient to prevent extreme fluid loss and to be life-saving
in this self-limiting disease. Moreover, testing CFTR
inhibitors in mouse models of SD [139] and for the
inhibition of cyst growth in polycystic kidney disease
[140], did not reveal evidence of serious side effects.
However, this does not preclude the occurrence of CF-
like pathology in humans, considering the more severe
lung and pancreatic phenotype in human CF patients.
Human testing will be important, especially given the
extreme susceptibility of CF patients to infection and
inflammation.
Opportunities
Despite the considerable limitations of current drugs
targeting CFTR and of therapies for SD in general,
recent advances in biotechnology and in the use of
computational tools could be instrumental in overcom-
ing some challenges and identifying lead compounds
for new effective small-molecule therapies.
Human enteroids present a novel tool to study
human intestinal ion transport physiology and patho-
physiology, as well as permitting novel and personal-
ized screens [141,142]. These ‘mini-gut’ structures can
be generated from the stem cells in intestinal biopsies
and grown in virtually unlimited amounts, either 3-di-
mensionally (3D) in Matrigel droplets, or 2-dimension-
ally (2D) on matrix-coated filters or micro-engineered
gut-on-a-chip devices [143,144]. The latter technique
can be used also to mimic peristalsis and fluid flow.
Whereas enteroids and colonoids remain reductionist
models, that is are missing the complexity of the native
tissue, this limitation can be overcome by co-culturing
the organoids with other cell types such as microbes,
immune cells, neural crest cells and mesenchymal cells
[144–146]. Although ‘basal out’ 3D organoids were the
first models to demonstrate, on the basis of CT- or
forskolin/cAMP-induced fluid secretion (FIS) assays, a
high functional expression of CFTR and its inhibition
by CFTR inhibitors [142], the poor accessibility of
their luminal compartment to enterotoxins (CT, STa)
and to CFTR- or CT-specific inhibitors makes them
less suitable for antidiarrhoeal drug screening. In con-
trast, 2D monolayers of enteroids and colonoids are
freely accessible at both the basolateral (serosal) side
and the apical (luminal) side, therefore bypassing the
need for microinjection of test compounds or
microbes. Moreover, unlike 3D organoids they allow
traditional ion transport studies, including electrical
measurements of CFTR-mediated Cl− secretory cur-
rents in Ussing chambers and NHE3 activity measure-
ments by multi-photon microscopy [147,148]. Human
intestinal organoids offer many advantages compared
with the cancer cell lines traditionally used in intestinal
ion transport studies. First, they are unique in their
capacity to allow personalized theratyping of drugs
that could be applied in ion transport diseases such as
cystic fibrosis and diarrhoeal disease [149,150]. Second,
they can be used to study segmental differences and
spatial differences along the crypt-villus axis at both a
macroscopic and microscopic level [151]. Third, goblet
cell-enriched organoid monolayers are capable of
building up a mucus layer at their luminal side which
mimics the barrier function of native epithelium
[152,153]. This allows the assessment of the impact of
the mucus barrier on the efficacy of luminally added
compounds, including CFTR inhibitors. Moreover,
approaches that aim to facilitate transport of antidiar-
rhoeal agents across the mucus layer, such as alginates
or nanoparticles, can be evaluated [154,155].
The past decades have seen a major increase in the
number of full-length ABC transporters for which we
have atomic-level models of 3D structure. Boosted by
this detailed information, a large number of functional
studies have been carried out, developing, refining and
testing hypotheses on how these proteins function. In
addition, for CFTR, the identification and develop-
ment of modulator drugs for treatment of CF has also
resulted in new tools, improving our ability to investi-
gate structure/function questions. We now have a dee-
per understanding of the protein structure and of the
dynamics underlying channel function [1]. Guided by
this knowledge, computational simulations and in sil-
ico screening algorithms will soon be used much more
effectively to identify and develop drugs targeting
CFTR.
Based on the molecular mechanisms by which small
molecules can affect CFTR (Fig. 5), which of the con-
formational changes underlying the gating cycle should
we attempt to target? Intervention at what steps would
be most suited for reversibly reducing anion flow
mediated by CFTR?
Preventing or slowing down the IF-to-OF transition
coupled to the opening of the CFTR pore might be an
achievable target. For CFTR this is the slowest step of
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the gating cycle (e.g. [23]), probably reflecting the large
conformational change required, thus small changes in
this microscopic rate could achieve large effects on
open probability. Several small molecules (including
zosuquidar, glibenclamide and the quinoline MsbA
inhibitors) are thought to act at this step on other
ABC systems, by binding to pockets formed in
between the transmembrane helices. CFTR’s unique
TMD2 structure, including an unwound TM8 might
provide an opportunity for selectivity. However, for
the moment, rational design of such small molecules is
not possible, because we do not know the final confor-
mational change underlying gate opening, nor the
detailed structure of the extracellular end of the CFTR
permeation pathway. This gap in our knowledge might
be filled soon as structural biologists prepare single
particles for cryo-EM analysis using lipid nanodiscs
(rather than detergent solubilization) to embed these
proteins in an environment closer to a lipid bilayer
membrane. In the meanwhile, an alternative strategy
could be to exploit ligand-based virtual screening tools
[156,157], using existing ligands as starting points for a
focused exploration of chemical space. Chemical ana-
logues identified in silico could be screened for effects
with 2D organoids and other high-throughput biologi-
cal assays [102,158,159]. CFTR ligands thought to act
at this step, albeit normally speeding up channel open-
ing (e.g. the quinoline compounds [98], 5-nitro-2-(3-
phenylpropylamino)benzoate [160,161] or VX-770
[162–164]), could also provide useful focus points, aim-
ing at identifying analogues acting as reverse agonist.
Finally, the putative mechanism of action of CFTRinh-
172 also suggests a conformational step, modulation
of which is worth exploring. The opening between
TM4 and TM6, corresponding to CFTR’s lateral por-
tal, is unique to the channel CFTR, and conservation
in this region – even among asymmetric ABC trans-
porters [15] is low. Small molecules, binding at this site
and triggering portal obstruction, could be designed to
reach a very high affinity, with minimal risk of simul-
taneously increasing off-target affinity.
Conclusions and perspectives
Among the many antidiarrhoeal therapies discussed
briefly in this review, inhibition of CFTR by orally
bioavailable compounds could potentially be highly
effective against SD caused by noninvasive pathogens
such as V. cholerae and ETEC strains. If readily avail-
able as emergency treatment, it could prevent death by
dehydration in particularly vulnerable individuals, such
as children, and slow the spread of infection. However,
the proper targeting of these inhibitors to CFTR in
the intestinal crypts, hampered by their convective
washout with secreted fluid and abundant mucus,
remains a major challenge. Another intrinsic limitation
of therapies based on CFTR inhibitors is their inabil-
ity to reactivate NHE3-mediated NaCl and fluid
absorption, in contrast to inhibitors of cAMP or
cGMP signalling. However, this constraint can be
overcome by combining CFTR inhibitor therapy with
ORS, thereby exploiting Na+-coupled glucose and fluid
absorption, which is not inhibited by the enterotoxins.
Finally, aside their potential therapeutic applica-
tions, CFTR inhibitors can also be used as tools to
elucidate CFTR gating dynamics and ABC transporter
mechanisms. As highlighted in this review, some com-
pounds can alter the function of a number of ABC
systems and comparing effects can lead to better mech-
anistic understanding, which in turn could guide
improvement of therapies. Glibenclamide prevents the
IF-to-OF transition in SUR1, but not in CFTR. Fur-
ther investigating whether this reflects CFTR’s unique
structure and protein dynamics at the extracellular end
of the TMDs (extracellular gate) or specific SUR1-
Kir6 interactions could have an impact on therapies
targeting both proteins. The MsbA inhibitors appear
to activate CFTR. As such, development of the inhibi-
tors for antibacterial therapy will need to take into
account any off-target effects on CFTR. On the other
hand, further investigation of their action on CFTR
could help clarify the still poorly understood opening
of the extracellular gate.
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